Monoclonal Antibodies, Oligonucleotides, and Metal Chelators Vary in their Effectiveness of Treating Prion Diseases

This paper evaluates the effectiveness of monoclonal antibodies (mAbs), antisense oligonucleotides (ASOs), and metal chelators for the treatment of prion diseases. Using data from current scientific journals and from biomedical research databases such as PubMed, this review compares the efficiency, limitations, and current progress of each approach. Current evidence suggests that mAbs show the greatest therapeutic promise. However, all treatment strategies are associated with off-target effects, though their severity is under debate. This result suggests a need for further research, particularly into ASOs and metal chelators, due to limited available studies.